首页 > 最新文献

Recent patents on anti-infective drug discovery最新文献

英文 中文
Meet Our Editorial Board Member 见见我们的编辑委员会成员
Q3 Medicine Pub Date : 2018-10-24 DOI: 10.2174/1574891x1301180927103550
A. di Biagio
{"title":"Meet Our Editorial Board Member","authors":"A. di Biagio","doi":"10.2174/1574891x1301180927103550","DOIUrl":"https://doi.org/10.2174/1574891x1301180927103550","url":null,"abstract":"","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x1301180927103550","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43086426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Selections. 专利选择。
Q3 Medicine Pub Date : 2018-06-06 DOI: 10.2174/1574891X1202180503125728
{"title":"Patent Selections.","authors":"","doi":"10.2174/1574891X1202180503125728","DOIUrl":"https://doi.org/10.2174/1574891X1202180503125728","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891X1202180503125728","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46387071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Biological Efficacy of Carvacrol Analogues. 香芹酚类似物的生物学功效。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1574891X14666181205111821
Zintle Mbese, Blessing Atim Aderibigbe

Background: Carvacrol is the major constituent of essential oils derived from plants. It exhibits antimicrobial, antioxidant, anticancer, anti-inflammatory, and anticholinesterase activity. The analogues of carvacrol can be prepared via selected synthetic routes, resulting in potent compounds.

Objective: Modifying carvacrol by the introduction of selected functionalities has the potential to enhance the biological activity of carvacrol. The functionalities on carvacrol such as the hydroxyl group, benzene ring and alkyl groups can be modified or used for hybridization with important pharmaceutical scaffolds.

Results: In one of the patents cited, EP1053744B1, the modification of the hydroxyl group and the introduction of allyl groups into the benzene ring resulted in carvacrol analogues with antibacterial activity. Modifying the hydroxyl group influenced the hydrophobicity of the analogues and the size of the ring substituent. The hydrophobicity and the size of the ring substituent influence the analogues interactions with bacterial cells. The analogues of carvacrol with anticancer activity were influenced by the position of the substituted groups on the benzene ring. Substituent introduced at the ortho and para- positions resulted in better antitumor activity when compared to the ones with substituents on the meta-position.

Conclusion: Based on several reports on cavarcrol analogues, more research on the development of carvacrol analogues will result in potent compounds that can overcome drug resistance which is currently a challenge in the treatment of diseases, such as bacterial infections, cancer, fungal infections etc. However, more biological evaluation is required in order to fully understand the mode of action of these analogues on selected pathogens.

背景:香芹酚是植物精油的主要成分。它具有抗菌、抗氧化、抗癌、抗炎和抗胆碱酯酶活性。香芹酚的类似物可以通过选定的合成路线制备,从而得到有效的化合物。目的:通过引入特定的功能修饰香芹酚,有可能提高香芹酚的生物活性。香芹酚上的羟基、苯环和烷基等官能团可以被修饰或用于与重要的药物支架的杂交。结果:在所引专利EP1053744B1中,对羟基进行修饰,并在苯环上引入烯丙基,得到了具有抗菌活性的香菜酚类似物。羟基的修饰影响了类似物的疏水性和环取代基的大小。疏水性和环取代基的大小影响类似物与细菌细胞的相互作用。香芹酚类似物的抗癌活性受其苯环取代基位置的影响。在邻位和对位上引入取代基比在中间位置上引入取代基的取代基具有更好的抗肿瘤活性。结论:基于一些关于卡瓦罗罗类似物的报道,对卡瓦罗罗类似物开发的更多研究将会产生有效的化合物来克服目前在细菌感染、癌症、真菌感染等疾病的治疗中所面临的挑战。然而,为了充分了解这些类似物对选定病原体的作用模式,需要更多的生物学评价。
{"title":"Biological Efficacy of Carvacrol Analogues.","authors":"Zintle Mbese,&nbsp;Blessing Atim Aderibigbe","doi":"10.2174/1574891X14666181205111821","DOIUrl":"https://doi.org/10.2174/1574891X14666181205111821","url":null,"abstract":"<p><strong>Background: </strong>Carvacrol is the major constituent of essential oils derived from plants. It exhibits antimicrobial, antioxidant, anticancer, anti-inflammatory, and anticholinesterase activity. The analogues of carvacrol can be prepared via selected synthetic routes, resulting in potent compounds.</p><p><strong>Objective: </strong>Modifying carvacrol by the introduction of selected functionalities has the potential to enhance the biological activity of carvacrol. The functionalities on carvacrol such as the hydroxyl group, benzene ring and alkyl groups can be modified or used for hybridization with important pharmaceutical scaffolds.</p><p><strong>Results: </strong>In one of the patents cited, EP1053744B1, the modification of the hydroxyl group and the introduction of allyl groups into the benzene ring resulted in carvacrol analogues with antibacterial activity. Modifying the hydroxyl group influenced the hydrophobicity of the analogues and the size of the ring substituent. The hydrophobicity and the size of the ring substituent influence the analogues interactions with bacterial cells. The analogues of carvacrol with anticancer activity were influenced by the position of the substituted groups on the benzene ring. Substituent introduced at the ortho and para- positions resulted in better antitumor activity when compared to the ones with substituents on the meta-position.</p><p><strong>Conclusion: </strong>Based on several reports on cavarcrol analogues, more research on the development of carvacrol analogues will result in potent compounds that can overcome drug resistance which is currently a challenge in the treatment of diseases, such as bacterial infections, cancer, fungal infections etc. However, more biological evaluation is required in order to fully understand the mode of action of these analogues on selected pathogens.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36753138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
HIV/AIDS Curable Study: New Forms of Therapeutic Trinity. 艾滋病可治愈性研究:治疗三位一体的新形式。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1574891X13666181026094526
Da-Yong Lu, Ting-Ren Lu, Hong-Ying Wu, Nagendra S Yarla, Jian Ding, Bin Xu

Background and aims: AIDS (acquired immune deficient syndrome), a deadly human infectious disease is caused by HIV (human immunodeficiency viruses) infection. Patient's mortality was eventually reduced to one-fourth by combined chemotherapy (usually 3 chemical drugs simultaneously) than earlier HIV/AIDS treatments (single drug or vaccine) in the clinic.

Results: Combined treatments against HIV/AIDS are still incurable for all patients despite a high rate of patient's survival. Basic viral pathological study and advancing drug development systems for curable medications are indispensable nowadays and in the future.

Conclusion: Up to date, therapeutic trinity (combined therapy) against HIV/AIDS is generally among chemical drugs. In this article, several forms of other therapeutic attempts for effectively curing efforts against HIV/AIDS are proposed-including the development of next generation therapeutic HIV vaccines and schedules, new categories of bio-therapy, different pathways of immune-modulation, herbal medicines in general (allopathic, Ayurveda and traditional Chinese medicines), high quality of physical exercises, and especially therapeutic combinations guided by latest medical discovery and principles (new forms of therapeutic trinity against HIV-induced pathogenesis and human mortality).

背景和目的:艾滋病(获得性免疫缺陷综合征)是由HIV(人类免疫缺陷病毒)感染引起的一种致命的人类传染病。通过联合化疗(通常同时使用3种化学药物),患者的死亡率最终降低到早期临床艾滋病毒/艾滋病治疗(单一药物或疫苗)的四分之一。结果:尽管艾滋病患者的生存率很高,但联合治疗对所有患者仍然是无法治愈的。现在和将来,基础的病毒病理研究和先进的药物开发系统对于可治愈的药物是必不可少的。结论:迄今为止,三位一体(联合治疗)治疗HIV/AIDS普遍属于化学药物。本文提出了几种有效治疗艾滋病毒/艾滋病的其他形式的治疗尝试,包括开发下一代治疗性艾滋病毒疫苗和时间表,新的生物疗法类别,免疫调节的不同途径,一般的草药(对抗疗法,阿育吠陀和传统中药),高质量的体育锻炼,特别是以最新医学发现和原理为指导的治疗组合(针对艾滋病毒引起的发病机制和人类死亡的新形式的三位一体治疗)。
{"title":"HIV/AIDS Curable Study: New Forms of Therapeutic Trinity.","authors":"Da-Yong Lu,&nbsp;Ting-Ren Lu,&nbsp;Hong-Ying Wu,&nbsp;Nagendra S Yarla,&nbsp;Jian Ding,&nbsp;Bin Xu","doi":"10.2174/1574891X13666181026094526","DOIUrl":"https://doi.org/10.2174/1574891X13666181026094526","url":null,"abstract":"<p><strong>Background and aims: </strong>AIDS (acquired immune deficient syndrome), a deadly human infectious disease is caused by HIV (human immunodeficiency viruses) infection. Patient's mortality was eventually reduced to one-fourth by combined chemotherapy (usually 3 chemical drugs simultaneously) than earlier HIV/AIDS treatments (single drug or vaccine) in the clinic.</p><p><strong>Results: </strong>Combined treatments against HIV/AIDS are still incurable for all patients despite a high rate of patient's survival. Basic viral pathological study and advancing drug development systems for curable medications are indispensable nowadays and in the future.</p><p><strong>Conclusion: </strong>Up to date, therapeutic trinity (combined therapy) against HIV/AIDS is generally among chemical drugs. In this article, several forms of other therapeutic attempts for effectively curing efforts against HIV/AIDS are proposed-including the development of next generation therapeutic HIV vaccines and schedules, new categories of bio-therapy, different pathways of immune-modulation, herbal medicines in general (allopathic, Ayurveda and traditional Chinese medicines), high quality of physical exercises, and especially therapeutic combinations guided by latest medical discovery and principles (new forms of therapeutic trinity against HIV-induced pathogenesis and human mortality).</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36608601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Current State of Nanomedicines in the Treatment of Topical Infectious Disorders. 纳米药物治疗局部感染性疾病的现状。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1574891X13666180529103804
Kanika Thakur, Gajanand Sharma, Bhupinder Singh, Sanjay Chhibber, Om P Katare

Background: Topical infections, involving a number of diseases such as impetigo, eczema, pustular acne, psoriasis and infected seborrheic dermatitis are one among the many challenges to health which stand out for their profound impact on human species. The treatment of topical infections has always been a difficult proposition because of the lack of efficacy of existing anti-infectives, longer period of treatment and yet incomplete recovery. The increasing emergence of antibiotic resistant bacterial strains like Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa undermines the need for the development of new delivery systems to enhance the therapeutic efficacy of existing topical anti-infectives.

Methods: The application of nanotechnology to medicine, or nanomedicine, is rapidly becoming a major driving force behind ongoing changes in the anti-infective field because of its interaction at the sub-atomic level with the skin tissue. The latter, in the current scenario, points towards vesicular carriers like liposomes, lipidic nanoparticles and silver nanoparticles. as the most promising drug delivery solutions for topical infection disorders. These have exhibited immense significance owing to their uniqueness to facilitate the interactions at interfaces with the barrier membranes.

Results: The present review summarizes the emerging efforts in combating topical infections particularly using nanomedicine based delivery systems as new tools to tackle the current challenges in treating infectious diseases. Besides, compiling various research reports, this article also includes formulation considerations, mechanisms of penetration and patents reported.

Conclusion: Despite the new emerging technologies and delivery systems, efforts are still needed in the right direction to combat this global challenge.

背景:局部感染,包括脓疱疮、湿疹、脓疱性痤疮、牛皮癣和感染性脂溢性皮炎等多种疾病,是对人类健康的诸多挑战之一,它们对人类物种产生了深远的影响。局部感染的治疗一直是一个困难的问题,因为现有的抗感染药物缺乏疗效,治疗时间较长,尚未完全恢复。金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌(MRSA)和铜绿假单胞菌等抗生素耐药菌株的不断出现,削弱了开发新的给药系统以增强现有局部抗感染药物治疗效果的必要性。方法:纳米技术在医学上的应用,或纳米医学,正迅速成为抗感染领域持续变化的主要驱动力,因为它在亚原子水平上与皮肤组织相互作用。在目前的情况下,后者指向囊状载体,如脂质体、脂质纳米颗粒和银纳米颗粒。作为局部感染疾病最有前途的药物递送解决方案。这些具有促进与屏障膜界面相互作用的独特性,因此具有巨大的意义。结果:本综述总结了在对抗局部感染方面的新进展,特别是利用基于纳米药物的给药系统作为新工具来应对当前治疗传染病的挑战。此外,本文还汇编了各种研究报告,包括配方考虑、渗透机制和专利报告。结论:尽管出现了新的技术和交付系统,但仍需要朝着正确的方向努力,以应对这一全球挑战。
{"title":"Current State of Nanomedicines in the Treatment of Topical Infectious Disorders.","authors":"Kanika Thakur,&nbsp;Gajanand Sharma,&nbsp;Bhupinder Singh,&nbsp;Sanjay Chhibber,&nbsp;Om P Katare","doi":"10.2174/1574891X13666180529103804","DOIUrl":"https://doi.org/10.2174/1574891X13666180529103804","url":null,"abstract":"<p><strong>Background: </strong>Topical infections, involving a number of diseases such as impetigo, eczema, pustular acne, psoriasis and infected seborrheic dermatitis are one among the many challenges to health which stand out for their profound impact on human species. The treatment of topical infections has always been a difficult proposition because of the lack of efficacy of existing anti-infectives, longer period of treatment and yet incomplete recovery. The increasing emergence of antibiotic resistant bacterial strains like Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa undermines the need for the development of new delivery systems to enhance the therapeutic efficacy of existing topical anti-infectives.</p><p><strong>Methods: </strong>The application of nanotechnology to medicine, or nanomedicine, is rapidly becoming a major driving force behind ongoing changes in the anti-infective field because of its interaction at the sub-atomic level with the skin tissue. The latter, in the current scenario, points towards vesicular carriers like liposomes, lipidic nanoparticles and silver nanoparticles. as the most promising drug delivery solutions for topical infection disorders. These have exhibited immense significance owing to their uniqueness to facilitate the interactions at interfaces with the barrier membranes.</p><p><strong>Results: </strong>The present review summarizes the emerging efforts in combating topical infections particularly using nanomedicine based delivery systems as new tools to tackle the current challenges in treating infectious diseases. Besides, compiling various research reports, this article also includes formulation considerations, mechanisms of penetration and patents reported.</p><p><strong>Conclusion: </strong>Despite the new emerging technologies and delivery systems, efforts are still needed in the right direction to combat this global challenge.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36136810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Nanomedicine Advances in Topical Infective and Non-Infective Skin Diseases Therapy. 纳米医学在局部感染性和非感染性皮肤病治疗中的进展。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1574891X1302181106123659
Mahfoozur Rahman, Sohail Akhter, Sarwar Beg

{"title":"Nanomedicine Advances in Topical Infective and Non-Infective Skin Diseases Therapy.","authors":"Mahfoozur Rahman,&nbsp;Sohail Akhter,&nbsp;Sarwar Beg","doi":"10.2174/1574891X1302181106123659","DOIUrl":"https://doi.org/10.2174/1574891X1302181106123659","url":null,"abstract":"<p><p></p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891X1302181106123659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36788419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Patent Selections. 专利选择。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1574891X1302181106123737

{"title":"Patent Selections.","authors":"","doi":"10.2174/1574891X1302181106123737","DOIUrl":"https://doi.org/10.2174/1574891X1302181106123737","url":null,"abstract":"<p><p></p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891X1302181106123737","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36788420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Patents on Light-Based Anti-Infective Approaches. 基于光的抗感染方法的最新专利。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1872213X11666171108104104
Imran Ahmed, Yanyan Fang, Min Lu, Quan Yan, Ahmed El-Hussein, Michael R Hamblin, Tianhong Dai

Background: Antibiotic resistance is one of the most serious health threats to modern medicine. The lack of potent antibiotics puts us at a disadvantage in the fight against infectious diseases, especially those caused by antibiotic-resistant microbial strains. To this end, an urgent need to search for alternative antimicrobial approaches has arisen. In the last decade, light-based anti-infective therapy has made significant strides in this fight to combat antibiotic resistance among various microbial strains. This method includes utilizing antimicrobial blue light, antimicrobial photodynamic therapy, and germicidal ultraviolet irradiation, among others. Light-based therapy is advantageous over traditional antibiotics in that it eradicates microbial cells rapidly and the likelihood of light-resistance development by microbes is low.

Methods: This review highlights the patents on light-based therapy that were filed approximately within the last decade and are dedicated to eradicating pathogenic microorganisms. The primary database that was used for the search was Google Patents. The searches were performed using the keywords including blue light, antimicrobial photodynamic therapy, ultraviolet irradiation, antibiotic resistance, disinfection, bacterium, fungus, and virus.

Results: Forty-five patents were obtained in our search: 9 patents for the antimicrobial blue light approach, 21 for antimicrobial photodynamic therapy, 11 for UV irradiation, and lastly 4 for other light-based anti-infective approaches. The treatments and devices discussed in this review are interestingly enough able to be used in various different functions and settings, such as dental applications, certain eye diseases, skin and hard surface cleansing, decontamination of internal organs (e.g., the stomach), decontamination of apparel and equipment, eradication of pathogenic microorganisms from buildings and rooms, etc. Most of the devices and inventions introduce methods of destroying pathogenic bacteria and fungi without harming human cells and tissues.

Conclusions: Light-based antimicrobial approaches hold great promise for the future in regards to treating antibiotic-resistant infections and related diseases.

背景:抗生素耐药性是现代医学面临的最严重的健康威胁之一。缺乏强效抗生素使我们在对抗传染病,尤其是抗生素耐药微生物菌株引起的传染病时处于不利地位。为此,迫切需要寻找替代抗菌方法。近十年来,光基抗感染疗法在抗击各种微生物菌株的抗生素耐药性方面取得了长足进步。这种方法包括利用抗菌蓝光、抗菌光动力疗法和紫外线杀菌照射等。与传统抗生素相比,光疗法的优势在于能迅速消灭微生物细胞,而且微生物对光产生抗药性的可能性较低:本综述重点介绍了大约在过去十年中申请的专门用于根除病原微生物的光疗法专利。搜索使用的主要数据库是谷歌专利。搜索使用的关键词包括蓝光、抗菌光动力疗法、紫外线照射、抗生素耐药性、消毒、细菌、真菌和病毒:搜索结果:我们获得了 45 项专利:其中 9 项专利涉及抗菌蓝光疗法,21 项涉及抗菌光动力疗法,11 项涉及紫外线照射,最后 4 项涉及其他基于光的抗感染疗法。有趣的是,本综述中讨论的治疗方法和设备可用于各种不同的功能和环境,如牙科应用、某些眼科疾病、皮肤和硬表面清洁、内脏器官(如胃)净化、服装和设备净化、消除建筑物和房间中的病原微生物等。大多数设备和发明都引入了在不伤害人体细胞和组织的情况下消灭病原细菌和真菌的方法:光基抗菌方法在治疗耐抗生素感染和相关疾病方面前景广阔。
{"title":"Recent Patents on Light-Based Anti-Infective Approaches.","authors":"Imran Ahmed, Yanyan Fang, Min Lu, Quan Yan, Ahmed El-Hussein, Michael R Hamblin, Tianhong Dai","doi":"10.2174/1872213X11666171108104104","DOIUrl":"10.2174/1872213X11666171108104104","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic resistance is one of the most serious health threats to modern medicine. The lack of potent antibiotics puts us at a disadvantage in the fight against infectious diseases, especially those caused by antibiotic-resistant microbial strains. To this end, an urgent need to search for alternative antimicrobial approaches has arisen. In the last decade, light-based anti-infective therapy has made significant strides in this fight to combat antibiotic resistance among various microbial strains. This method includes utilizing antimicrobial blue light, antimicrobial photodynamic therapy, and germicidal ultraviolet irradiation, among others. Light-based therapy is advantageous over traditional antibiotics in that it eradicates microbial cells rapidly and the likelihood of light-resistance development by microbes is low.</p><p><strong>Methods: </strong>This review highlights the patents on light-based therapy that were filed approximately within the last decade and are dedicated to eradicating pathogenic microorganisms. The primary database that was used for the search was Google Patents. The searches were performed using the keywords including blue light, antimicrobial photodynamic therapy, ultraviolet irradiation, antibiotic resistance, disinfection, bacterium, fungus, and virus.</p><p><strong>Results: </strong>Forty-five patents were obtained in our search: 9 patents for the antimicrobial blue light approach, 21 for antimicrobial photodynamic therapy, 11 for UV irradiation, and lastly 4 for other light-based anti-infective approaches. The treatments and devices discussed in this review are interestingly enough able to be used in various different functions and settings, such as dental applications, certain eye diseases, skin and hard surface cleansing, decontamination of internal organs (e.g., the stomach), decontamination of apparel and equipment, eradication of pathogenic microorganisms from buildings and rooms, etc. Most of the devices and inventions introduce methods of destroying pathogenic bacteria and fungi without harming human cells and tissues.</p><p><strong>Conclusions: </strong>Light-based antimicrobial approaches hold great promise for the future in regards to treating antibiotic-resistant infections and related diseases.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938159/pdf/nihms922369.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35594921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short Antimicrobial Peptides. 短抗菌肽。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1574891X13666180628105928
Komal Sharma, Shams Aaghaz, Kitika Shenmar, Rahul Jain

Background: After the era of serendipitous discovery of penicillin and outburst in the discovery and development of highly efficient antibiotics, a surge in resistance against the target specific drugs was observed, primarily due to a combination of selective pressure of antibiotics use and spontaneous mutations. As per the World Health Organization, antibiotic resistance is one of the greatest threats to the mankind.

Objective: Short antimicrobial peptides (SAMPs) can be considered as a viable therapeutic alternative to conventional antibiotics in tackling resistant microbes. The ubiquitous nature of SAMPs combined with their ability to act via non-specific modes of action, high activity against a wide spectrum of drug-sensitive and drug-resistant microbes, and relative insusceptibility against the development of resistance adds to their desirability as new generation antibiotics.

Results: Due to the natural tendency of peptides to get metabolized by proteolytic enzymes, modification of naturally occurring SAMPs is desirable. The modifications can be done either by incorporating unnatural or modified amino acids into the peptide chain or by protecting C and N termini. The characteristic feature of SAMPs is their hydrophobicity and cationicity, which aid in the effective killing of microbes by selectively binding target and lysing the microbial cells with less deleterious effects on the host cells as compared to AMPs and other conventional antibiotics.

Conclusion: Herein, we discussed the arsenal of short peptides and peptidomimetics starting from the smallest unit possible - a dipeptide to a decapeptide along with their activity profiles as antimicrobials. Recently, various SAMPs have paved their ways from in vitro studies to clinical trials, as evident from the most recent patent (EP1951194) on oral hygiene. This step by step growth of SAMPs has restored the hope in peptide-based therapeutics, which may prove an essential tool in eradicating antimicrobial resistance and tackling various microbial infections.

背景:在偶然发现青霉素和发现和开发高效抗生素的爆发时代之后,观察到对目标特异性药物的耐药性激增,主要是由于抗生素使用的选择压力和自发突变的结合。据世界卫生组织称,抗生素耐药性是人类面临的最大威胁之一。目的:短抗菌肽(SAMPs)可以被认为是治疗耐药微生物的一种可行的替代方法。SAMPs的普遍特性,加上它们通过非特异性作用方式起作用的能力,对广泛的药物敏感和耐药微生物的高活性,以及对耐药性发展的相对不敏感,这些都增加了它们作为新一代抗生素的可取性。结果:由于多肽自然倾向于被蛋白水解酶代谢,因此需要对天然存在的SAMPs进行修饰。修饰可以通过在肽链中加入非天然或修饰的氨基酸或通过保护C和N端来完成。SAMPs的特点是其疏水性和阳离子性,与AMPs和其他常规抗生素相比,SAMPs通过选择性结合靶点并裂解微生物细胞来有效杀死微生物,对宿主细胞的有害作用较小。结论:在这里,我们讨论了短肽和仿肽的武器库,从最小的单位开始-二肽到十肽,以及它们作为抗菌剂的活性概况。最近,各种samp已经从体外研究到临床试验铺平了道路,这一点从最近的口腔卫生专利(EP1951194)中可以看出。SAMPs的逐步增长恢复了基于肽的治疗方法的希望,这可能被证明是消除抗菌素耐药性和解决各种微生物感染的重要工具。
{"title":"Short Antimicrobial Peptides.","authors":"Komal Sharma,&nbsp;Shams Aaghaz,&nbsp;Kitika Shenmar,&nbsp;Rahul Jain","doi":"10.2174/1574891X13666180628105928","DOIUrl":"https://doi.org/10.2174/1574891X13666180628105928","url":null,"abstract":"<p><strong>Background: </strong>After the era of serendipitous discovery of penicillin and outburst in the discovery and development of highly efficient antibiotics, a surge in resistance against the target specific drugs was observed, primarily due to a combination of selective pressure of antibiotics use and spontaneous mutations. As per the World Health Organization, antibiotic resistance is one of the greatest threats to the mankind.</p><p><strong>Objective: </strong>Short antimicrobial peptides (SAMPs) can be considered as a viable therapeutic alternative to conventional antibiotics in tackling resistant microbes. The ubiquitous nature of SAMPs combined with their ability to act via non-specific modes of action, high activity against a wide spectrum of drug-sensitive and drug-resistant microbes, and relative insusceptibility against the development of resistance adds to their desirability as new generation antibiotics.</p><p><strong>Results: </strong>Due to the natural tendency of peptides to get metabolized by proteolytic enzymes, modification of naturally occurring SAMPs is desirable. The modifications can be done either by incorporating unnatural or modified amino acids into the peptide chain or by protecting C and N termini. The characteristic feature of SAMPs is their hydrophobicity and cationicity, which aid in the effective killing of microbes by selectively binding target and lysing the microbial cells with less deleterious effects on the host cells as compared to AMPs and other conventional antibiotics.</p><p><strong>Conclusion: </strong>Herein, we discussed the arsenal of short peptides and peptidomimetics starting from the smallest unit possible - a dipeptide to a decapeptide along with their activity profiles as antimicrobials. Recently, various SAMPs have paved their ways from in vitro studies to clinical trials, as evident from the most recent patent (EP1951194) on oral hygiene. This step by step growth of SAMPs has restored the hope in peptide-based therapeutics, which may prove an essential tool in eradicating antimicrobial resistance and tackling various microbial infections.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891X13666180628105928","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36266176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Antibacterial Activity of Gold Nanoparticles Conjugated by Aminoglycosides Against A. baumannii Isolates from Burn Patients. 氨基糖苷偶联金纳米颗粒对烧伤鲍曼不动杆菌的抗菌活性研究。
Q3 Medicine Pub Date : 2018-01-01 DOI: 10.2174/1574891X13666180828115543
Mehdi Rostami Rad, Hossein Kazemian, Fateme Yazdani, Mohammad Reza Zand Monfared, Hoseinali Rahdar, Ali Javadi, Mansoor Kodori

Background and objective: Today, resistance to multiple classes of antibiotics, and notably to the β-lactam and aminoglycosides in A. baumannii is becoming a great problem and it necessitates to make a new approach to combat with multidrug-resistant (MDR), extensive drug-resistance (XDR) or Pandrug-resistant (PDR) isolates. In this case, a new strategy and ways should be designed and introduced against such infections. Therefore the aim of the present study was the evaluation of antibacterial activity of nanoconjugate gentamicin and amikacin with gold against clinical isolates of A. baumannii that were collected from burn wound infection. There are some patents of gold nanoparticles that are conjugated with antibiotics (WO2017161296A1, US20090181101A1).

Methods: Eighteen A. baumannii were collected from burn wound infections. For confirmation and detection of aminoglycoside-resistant genes, PCR was carried out. Gold nanoparticles and nanoconjugates were prepared according to the protocol. For the evaluation of the nanoconjugate, Dynamic light cattering, Transmission electron microscopy and FTIR Analysis were carried out. Then, the antibacterial activity of nanoconjugates was conducted by using micro broth dilution method.

Result: Prevalence of aminoglycoside-resistant genes was aacC1, aphA6, aadA1, aadB genes 55.5%, 22.2%, 38.8% and 22.2% respectively. Synthesis of bare nanoconjugates resulted in nanoparticle in a size of 10 nm. Amikacin bound to Gnps showed excellent antibacterial activity (94.5%) and just one isolate showed intermediate resistance. Also, gentamicin bound to Gnps had a good antimicrobial effect (50%) in contrast to gentamicin alone.

Conclusion: Our study showed that a combination of amikacin and gentamicin with Gnps has a significant antibacterial efficiency against clinical isolates of A. baumannii. Gnps can be used as extraordinary molecular carriers for targeting, and delivery of the antibiotic molecules to the specific infection.

背景与目的:鲍曼不饱和杆菌对多种抗生素的耐药,特别是对β-内酰胺和氨基糖苷类抗生素的耐药已成为一个严重的问题,因此有必要制定新的方法来对抗多重耐药(MDR)、广泛耐药(XDR)或泛耐药(PDR)分离株。在这种情况下,应该设计和采用新的策略和方法来防止这种感染。因此,本研究的目的是评价纳米结合庆大霉素和含金阿米卡星对烧伤创面感染临床分离鲍曼不动杆菌的抗菌活性。与抗生素偶联的金纳米颗粒有一些专利(WO2017161296A1, US20090181101A1)。方法:采集烧伤创面感染鲍曼不动杆菌18只。为确认和检测氨基糖苷耐药基因,采用PCR方法。根据该方案制备了金纳米颗粒和纳米缀合物。为了对纳米共轭物进行评价,进行了动态光散射、透射电镜和红外光谱分析。然后,采用微肉汤稀释法对纳米缀合物进行抑菌活性测定。结果:氨基糖苷耐药基因为aacC1、aphA6、aadA1、aadB基因,分别占55.5%、22.2%、38.8%和22.2%。裸纳米缀合物的合成得到了10 nm大小的纳米颗粒。与Gnps结合的阿米卡星具有良好的抗菌活性(94.5%),仅有1株菌株表现出中等耐药性。与单独使用庆大霉素相比,与Gnps结合的庆大霉素具有良好的抗菌效果(50%)。结论:本研究表明,阿米卡星、庆大霉素联合Gnps对鲍曼不动杆菌临床分离株具有显著的抗菌效果。Gnps可以作为特殊的分子载体,用于靶向和递送抗生素分子到特定的感染。
{"title":"Antibacterial Activity of Gold Nanoparticles Conjugated by Aminoglycosides Against <i>A. baumannii</i> Isolates from Burn Patients.","authors":"Mehdi Rostami Rad,&nbsp;Hossein Kazemian,&nbsp;Fateme Yazdani,&nbsp;Mohammad Reza Zand Monfared,&nbsp;Hoseinali Rahdar,&nbsp;Ali Javadi,&nbsp;Mansoor Kodori","doi":"10.2174/1574891X13666180828115543","DOIUrl":"https://doi.org/10.2174/1574891X13666180828115543","url":null,"abstract":"<p><strong>Background and objective: </strong>Today, resistance to multiple classes of antibiotics, and notably to the β-lactam and aminoglycosides in A. baumannii is becoming a great problem and it necessitates to make a new approach to combat with multidrug-resistant (MDR), extensive drug-resistance (XDR) or Pandrug-resistant (PDR) isolates. In this case, a new strategy and ways should be designed and introduced against such infections. Therefore the aim of the present study was the evaluation of antibacterial activity of nanoconjugate gentamicin and amikacin with gold against clinical isolates of A. baumannii that were collected from burn wound infection. There are some patents of gold nanoparticles that are conjugated with antibiotics (WO2017161296A1, US20090181101A1).</p><p><strong>Methods: </strong>Eighteen A. baumannii were collected from burn wound infections. For confirmation and detection of aminoglycoside-resistant genes, PCR was carried out. Gold nanoparticles and nanoconjugates were prepared according to the protocol. For the evaluation of the nanoconjugate, Dynamic light cattering, Transmission electron microscopy and FTIR Analysis were carried out. Then, the antibacterial activity of nanoconjugates was conducted by using micro broth dilution method.</p><p><strong>Result: </strong>Prevalence of aminoglycoside-resistant genes was aacC1, aphA6, aadA1, aadB genes 55.5%, 22.2%, 38.8% and 22.2% respectively. Synthesis of bare nanoconjugates resulted in nanoparticle in a size of 10 nm. Amikacin bound to Gnps showed excellent antibacterial activity (94.5%) and just one isolate showed intermediate resistance. Also, gentamicin bound to Gnps had a good antimicrobial effect (50%) in contrast to gentamicin alone.</p><p><strong>Conclusion: </strong>Our study showed that a combination of amikacin and gentamicin with Gnps has a significant antibacterial efficiency against clinical isolates of A. baumannii. Gnps can be used as extraordinary molecular carriers for targeting, and delivery of the antibiotic molecules to the specific infection.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36436435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Recent patents on anti-infective drug discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1